Quynh le, DO
Surgical Oncology · Bellingham, WANPI 1588056568
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Dilon Technologies, Inc. accounts for 63.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $2,503 and has fallen 53.4% since, to $1,165 in 2025. That places this record below the midpoint for surgical oncology clinicians in WA, where the typical reported total is $5,112.
Across 49 payments — averaging $106.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dilon Technologies, Inc.$3K
- Elucent Medical$754
- Vector Surgical, LLC$682
- Leica Microsystems Inc.$138
- Merit Medical Systems Inc$120
- AstraZeneca$112
- plus $124 from 2 others
What the payments were for
- Travel & lodging$4849%
- Food & beverage$4,74891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dilon Technologies, Inc. | 38 | $3,303 |
| Elucent Medical | 2 | $754 |
| Vector Surgical, LLC | 4 | $682 |
| Leica Microsystems Inc. | 1 | $138 |
| Merit Medical Systems Inc | 1 | $120 |
| AstraZeneca | 1 | $112 |
| Medtronic | 1 | $95 |
| Myriad Genetic Laboratories, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HemoBlast Bellows$2,473
- Savi SCOUT$239
- NEOPROBE$138
- LYNPARZA$112
How this compares
$5,232 in reported general payments places this provider in the 50th percentile of 31 surgical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Bellingham
- Cary KaufmanBellingham$171K
- Flavio RochaSeattle$27K
- Evan OngSeattle$18K
- Benjamin AndersonSeattle$15K
- Kevin LabadieSeattle$11K
- Richard SmithTacoma$10K
- Max SeatonSpokane Valley$9K
- Jeremy SharibSeattle$9K
- Harveshp MogalSeattle$8K
- Meghan FlanaganSeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.